Patents by Inventor Kelli E. Smith
Kelli E. Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20020151705Abstract: This invention provides a recombinant nucleic acid comprising a nucleic acid encoding a mammalian SNORF49 receptor, wherein the mammalian receptor-encoding nucleic acid hybridizes under high stringency conditions to a nucleic acid encoding a human SNORF49 receptor and having a sequence identical to the sequence of the human SNORF49 receptor-encoding nucleic acid contained in plasmid pEXJ.T73BS-hSNORF49-f (Patent Deposit Designation PTA-659). This Invention further provides a recombinant nucleic acid comprising a nucleic acid encoding a human SNORF49 receptor, wherein the human SNORF49 receptor comprises an amino acid sequence identical to the sequence of the human SNORF49 receptor encoded by the shortest open reading frame indicated in FIGS. 1A-1B (SEQ ID NO: 1).Type: ApplicationFiled: December 11, 2001Publication date: October 17, 2002Inventors: Kelli E. Smith, Yong Quan
-
Publication number: 20020077469Abstract: This invention provides a recombinant nucleic acid comprising a nucleic acid encoding a mammalian SNORF11 receptor, wherein the mammalian receptor-encoding nucleic acid hybridizes under high stringency conditions to (a) a nucleic acid encoding a human SNORF11 receptor and having a sequence identical to the sequence of the human SNORF11 receptor-encoding nucleic acid contained in plasmid pEXJRHT3T7-hSNORF11-f (ATCC Accession No. ______ ) or (b) a nucleic acid encoding a rat SNORF11 receptor and having a sequence identical to the sequence of the rat SNORF11 receptor-encoding nucleic acid contained in plasmid pcDNA3.1-rSNORF11-f (ATCC Accession No. ______ ). This invention further provides a recombinant nucleic acid comprising a nucleic acid encoding a human SNORF11 receptor, wherein the human SNORF11 receptor comprises an amino acid sequence identical to the sequence of the human SNORF11 receptor encoded by the shortest open reading frame indicated in FIGS. 1A-1B (Seq. I.D. No. 1).Type: ApplicationFiled: July 2, 2001Publication date: June 20, 2002Inventors: Beth E. Borowsky, Yong Quan, Kelli E. Smith
-
Patent number: 6368812Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: GrantFiled: April 9, 1998Date of Patent: April 9, 2002Assignee: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Beth Borowsky, Kelli E. Smith, Theresa A. Branchek, Christophe P. G. Gerald, Kenneth A. Jones
-
Patent number: 6329197Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: GrantFiled: July 23, 1997Date of Patent: December 11, 2001Assignee: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Beth Borowsky, Kelli E. Smith
-
Patent number: 6287788Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: GrantFiled: November 25, 1998Date of Patent: September 11, 2001Assignee: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Beth Borowsky, Kelli E. Smith, Theresa A. Branchek, Christophe P. G. Gerald, Kenneth A. Jones
-
Publication number: 20010009766Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: ApplicationFiled: July 23, 1997Publication date: July 26, 2001Inventors: JONATHAN A. BARD, BETH BOROWSKY, KELLI E. SMITH
-
Patent number: 6225115Abstract: This invention provides isolated nucleic acid molecules encoding two mammalian GABA transporters, a mammalian taurine transporter and two human GABA transporters; methods of isolating these nucleic acid molecules and vectors comprising such nucleic acid molecules as well as mammalian cells comprising such vectors. Nucleic acid probes for detecting nucleic acid molecules encoding mammalian or human GABA transporters, or mammalian or human taurine transporters; antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian GABA or taurine transporter or human GABA or taurine transporter; and antibodies to the mammalian GABA or taurine transporters, or human GABA or taurine transporters are provided. Pharmaceutical compounds related to mammalian GABA or taurine transporters and to human GABA or taurine transporters are provided.Type: GrantFiled: June 30, 1999Date of Patent: May 1, 2001Assignee: Synaptic Pharmaceutical CorporationInventors: Kelli E. Smith, Laurence A. Borden, Richard L. Weinshank, Paul R. Hartig
-
Patent number: 6127131Abstract: This invention provides isolated nucleic acid molecules encoding a mammalian glycine transporter, isolated nucleic acid molecules encoding a human glycine transporter, isolated proteins which are mammalian glycine transporter proteins, isolated proteins which are human glycine transporter proteins, vectors comprising isolated nucleic acid molecules encoding a mammalian or a human glycine transporter, mammalian cells comprising such vectors, antibodies directed to a mammamlian glycine transporter, antibodies directed to a human glycine transporter, nucleic acid probes useful for detecting nucleic acid encoding mammalian glycine transporter, nucleic acid probes useful for detecting nucleic acid encoding human glycine transporter, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian glycine transporter, antisense oligonucleotides complementary to any sequences of a nucleic said molecule which encodes a human glycine transporter, pharmaceutical compounds rType: GrantFiled: May 26, 1998Date of Patent: October 3, 2000Assignee: Synaptic Pharmaceutical CorporationInventors: Kelli E. Smith, Laurence A. Borden, Theresa Branchek, Paul R. Hartig, Richard L. Weinshank
-
Patent number: 5972624Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising an isolated nucleic acid encoding a galanin receptor, cells comprising such vectors, antibodies directed to the galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding galanin receptors, antisense oligonucleotides complementary to unique sequences of a nucleic acid encoding a galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant galanin receptor, as well as methods of determining binding of compounds to the galanin receptor.Type: GrantFiled: April 1, 1996Date of Patent: October 26, 1999Assignee: Synaptic Pharmaceutical CorporationInventors: Kelli E. Smith, Christophe P. G. Gerald, Richard L. Weinshank, David Linemeyer, Theresa Branchek, Carlos Forray
-
Patent number: 5766848Abstract: This invention provides an isolated nucleic acid molecules encoding mammalian betaine/GABA transporters, including a human betaine/GABA transporter. This invention further provides vectors comprising said isolated nucleic acid molecules, and mammalian cells comprising such vectors. This invention further provides isolated mammalian and human betaine/GABA transporter proteins and antibodies directed thereto. This invention provides nucleic acid molecule probes useful for detecting nucleic acid molecules encoding mammalian or human betaine/GABA transporters, antisense oligonucleotides complementary to any sequences of a nucleic acid molecules which encode a mammalian or human betaine/GABA transporter. This invention further provides pharmaceutical compounds related to mammalian and human betaine/GABA transporters, and nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian or human betaine/GABA transporter.Type: GrantFiled: August 16, 1994Date of Patent: June 16, 1998Assignee: Synaptic Pharmaceutical CorporationInventors: Laurence A. Borden, Kelli E. Smith, Richard L. Weinshank
-
Patent number: 5756348Abstract: This invention provides isolated nucleic acid molecules encoding a mammalian glycine transporter, isolated nucleic acid molecules encoding a human glycine transporter, isolated proteins which are mammalian glycine transporter proteins, isolated proteins which are human glycine transporter proteins, vectors comprising isolated nucleic acid molecules encoding a mammalian or a human glycine transporter, mammalian cells comprising such vectors, antibodies directed to a mammalian glycine transporter, antibodies directed to a human glycine transporter, nucleic acid probes useful for detecting nucleic acid encoding mammalian glycine transporter, nucleic acid probes useful for detecting nucleic acid encoding human glycine transporter, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian glycine transporter, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human glycine transporter, pharmaceutical compounds reType: GrantFiled: November 10, 1994Date of Patent: May 26, 1998Assignee: Synaptic Pharmaceutical CorporationInventors: Kelli E. Smith, Laurence A. Borden, Theresa Branchek, Paul R. Hartig, Richard L. Weinshank
-
Patent number: 5712148Abstract: This invention provides an isolated nucleic acid molecule encoding a mammalian betaine/GABA transporter, an isolated nucleic acid molecule encoding a human betaine/GABA transporter, an isolated protein which is a mammalian betaine/GABA transporter, an isolated protein which is a human betaine/GABA transporter, vectors comprising an isolated nucleic acid molecule encoding a mammalian betaine/GABA transporter, vectors comprising an isolated nucleic acid molecule encoding a human betaine/GABA transporter, mammalian cells comprising such vectors, antibodies directed to the mammalian betaine/GABA transporter and antibodies directed to the human betaine/GABA transporter, nucleic acid probes useful for detecting nucleic acid molecules encoding mammalian betaine/GABA transporters and human betaine/GABA transporters, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian betaine/GABA transporter or a human betaine/GABA transporter, pharmaceutical compounds relateType: GrantFiled: October 17, 1995Date of Patent: January 27, 1998Assignee: Synaptic Pharmaceutical CorporationInventors: Laurence A. Borden, Kelli E. Smith, Richard L. Weinshank
-
Patent number: 5658786Abstract: This invention provides isolated nucleic acid molecules encoding two mammalian GABA transporters, a mammalian taurine transporter and two human GABA transporters and methods of isolating these nucleic acid molecules. Further provided are vectors comprising the nucleic acid molecules as well as mammalian cells comprising such vectors, and antibodies directed to the GABA and taurine transporters. Nucleic acid probes useful for detecting nucleic acid molecules encoding GABA and taurine transporters are also provided. Antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a GABA or taurine transporter are further provided. Pharmaceutical compounds related to GABA and taurine transporters are provided. Nonhuman transgenic animals which express DNA encoding a normal or a mutant GABA or taurine transporter are also provided.Type: GrantFiled: December 19, 1994Date of Patent: August 19, 1997Assignee: Synaptic Pharmaceutical CorporationInventors: Kelli E. Smith, Richard L. Weinshank, Laurence A. Borden, Paul R. Hartig
-
Patent number: 5559021Abstract: This invention provides an isolated nucleic acid molecule encoding a mammalian rB21a transporter, an isolated protein which is a mammalian rB21a transporter, vectors comprising an isolated nucleic acid molecule encoding a mammalian rB21a transporter, mammalian cells comprising such vectors, antibodies directed to the mammalian rB21a transporter, nucleic acid probes useful for detecting a nucleic acid molecule encoding mammalian rB21a transporter, antisense oligonucleotides complementary to any unique sequences of a nucleic acid molecule which encodes a mammalian rB21a transporter, pharmaceutical compounds related to mammalian rB21a transporter, and nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian rB21a transporter. This invention further provides methods for determining substrate binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with the mammalian rB21a transporter.Type: GrantFiled: November 9, 1993Date of Patent: September 24, 1996Assignee: Synaptic Pharmaceutical CorporationInventors: Kelli E. Smith, Richard L. Weinshank